Trials / Unknown
UnknownNCT03987815
Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
Neoadjuvant Nivolumab for Operable Esophageal Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Nivolumab |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2021-12-31
- Completion
- 2022-07-31
- First posted
- 2019-06-17
- Last updated
- 2020-12-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03987815. Inclusion in this directory is not an endorsement.